Optimisation of in vitro assays for accurate risk assessment of T-cell responses to biologics with potential immune liabilities. (PubMed, Arch Toxicol) - Sep 20, 2026 - "A stepwise approach to explore immunogenicity to biologics was developed by; (1) assessing the sensitivity of existing PBMC stimulation assays, (2) optimisation of a DC: T-cell co-culture assay, (3) definition of immune epitopes using rituximab MHC class II-binding peptides...These data indicate that DC: T-cell co-cultures and cloning methods should be used alongside epitope prediction tools to assess T-cell responses to biologics with potential immune liabilities. Implementing the stepwise approach outlined could identify high risk molecules early in development and highlight "hotspot" regions of molecules for risk mitigation."
Journal • Preclinical • CD4 • IFNG
|
|
Catherine J Betts; Dean J Naisbitt; Georgia Wells; Katy Saide; Liam Farrell; Lonnie MacDonald; Sophie Grice; Xiaoli Meng
|